Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:
11:00
TUAB0101
Comparative effectiveness of first-line antiretroviral therapy regimens: Results from a large real-world cohort in Brazil after the implementation of Dolutegravir
Mariana Veloso Meireles, Ministry of Health of Brazil, Brazil
Abstract
Slides
11:15
TUAB0102
Simplification to dolutegravir monotherapy is non-inferior compared to continuation of combination antiretroviral therapy in patients who initiated combination antiretroviral therapy during primary HIV infection: A randomized, controlled, non-inferiority trial
Dominique Laurent Braun, University Hospital Zurich, Switzerland
Abstract
Slides
11:30
TUAB0103
Dolutegravir monotherapy versus dolutegravir/abacavir/lamivudine for HIV-1-infected virologically suppressed patients: Results from the randomized non-inferiority MONCAY trial
Laurent Hocqueloux, CHR d'Orléans - La Source, France
Abstract
Slides
11:45
TUAB0104
A phase 3b, open-label, pilot study to evaluate switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in virologically-suppressed HIV-1 infected adult subjects harboring the NRTI resistance mutation M184V and/or M184I (GS-US-292-1824)
Ignacio Perez Valero, Unidad VIH - Hospital Universitario La Paz, Spain
Abstract
Slides
12:00
TUAB0106LB
Non-inferior efficacy of dolutegravir (DTG) plus lamivudine (3TC) versus DTG plus tenofovir/emtricitabine (TDF/FTC) fixed-dose combination in antiretroviral treatment-naïve adults with HIV-1 infection – interim data from the GEMINI Studies
Pedro Cahn, Fundacion Huesped, Argentina
Abstract
Slides
12:15
TUAB0107LB
Non-inferior efficacy for darunavir/ritonavir 400/100 mg once daily versus lopinavir/ritonavir, for patients with HIV RNA below 50 copies/mL in South Africa: The 48-week WRHI 052 study
Francois Venter, University of Witwatersrand, South Africa
Abstract
Slides
AUTHOR
SUMMARY
HIGHLIGHTS
CRITICAL ASSESSMENT